Roche Profit Shows New Drugs Taking Off, Old Ones Dragging

Updated on

Roche Holding AG’s first-half earnings showed little change as the Swiss franc’s strength and competition for aging medicines wiped out the impact of the drugmaker’s new stable of therapies.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.